Tag: ABT-414
Depatuxizumab Mafodotin Did Not Demonstrate Survival Benefit in INTELLANCE-1 Study
Depatuxizumab mafodotin (also known as Depatux-M, and previously known as ABT-414), an antibody-drug conjugate (ADC) being developed by AbbVie, did not demonstrate a survival...
Rare Pediatric Disease Designation for ABT-414 for the Treatment of a...
The U.S. Food and Drug Administration (FDA) has a granted Rare Pediatric Disease Designation for AbbVie's ABT-414, an investigational antibody-drug conjugate (ADC) targeting the...
ABT-414 Shows Encouraging Phase I Results in Monotherapy in Patients with...
Safety and preliminary efficacy data from a phase I study of ABT-414 (AbbVie) – an investigational antibody drug conjugate or ADC for the treatment of...
AbbVie Demonstrates Progress in Oncology Research at ASCO 2016
Chemotherapy remains the standard of care in the treatment of many types of cancer. However, one of the problems with chemotherapeutics is that it...
Clinical Updates Confirming Advances and Meaningful Benefits for Patients
Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...
ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...
Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...
Expanding Oncology Presence: AbbVie Acquires Stemcentrx
AbbVie, a global biopharmaceutical company has agreed to acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T), also known as SC16LD6.5, which is currently...
Randomized Phase I Trial Results of ABT-414 In Patients with Glioblastoma...
Updated interim results from a Phase I clinical trial of ABT-414 (AbbVie) in patients with glioblastoma multiforme (GBM), an aggressive form of brain cancer,...
Initial Phase I Trial Results of anti-EGFR drug ABT-414 in the...
With a median survival between 1 and 2 years and no long-term curative treatments, the management of patients with Glioblastoma Multiforme (GBM), the most common and most aggressive type of malignant primary brain tumor, remains challenging.
Phase I Trial Results in GBM Lead to Orphan Drug Designation...
The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to AbbVie's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with glioblastoma multiform.
